Related Experiment Videos
Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy
1Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Abstract:
To examine the effects of endogenous thromboxane A2 on the development of diabetic nephropathy, we administered OKY-046, an inhibitor of thromboxane synthesis, to streptozotocin-induced diabetic rats. Animals were divided into three groups; nondiabetic control, diabetic, and diabetic with OKY-046, and were sacrificed 16 weeks after experimental procedures. The chronic oral administration of OKY-046 to diabetic rats significantly decreased plasma and urinary thromboxane B2 levels. Urinary protein excretion and serum glucose levels were significantly lower in the OKY-046-treated diabetic rats than in the untreated diabetics (60.8 +/- 23.2 vs. 94.1 +/- 33.4 mg/day in the 16th week, p less than 0.05 and 424.4 +/- 93.3 vs. 614.4 +/- 102.3 mg/dl in the 16th week, p less than 0.01, respectively). Platelet aggregation was inhibited by OKY-046. Blood urea nitrogen was unaffected. Ultrastructural examination revealed that the thickness of glomerular basement membrane was markedly thinner in the OKY-046-treated diabetic rats than in the untreated diabetics (197.4 +/- 29.6 vs. 288.6 +/- 46.9 nm, p less than 0.01). These results suggest that thromboxane A2 may play an important role in the development and progression of diabetic nephropathy in rats.
Insights
Inhibiting thromboxane synthesis with OKY-046 reduced diabetic nephropathy markers in rats. This suggests thromboxane A2 (TXA2) plays a key role in diabetic kidney disease progression.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy is a major complication of diabetes mellitus.
- Endogenous thromboxane A2 (TXA2) is implicated in kidney disease development.
Purpose of the Study:
- To investigate the role of endogenous TXA2 in diabetic nephropathy.
- To evaluate the effects of a thromboxane synthesis inhibitor, OKY-046, on diabetic kidney disease in a rat model.
Main Methods:
- Streptozotocin-induced diabetic rats were treated with OKY-046 or vehicle.
- Plasma and urinary thromboxane B2 levels, urinary protein excretion, serum glucose, and glomerular basement membrane thickness were measured.
- Platelet aggregation and blood urea nitrogen were also assessed.
Main Results:
- OKY-046 significantly reduced thromboxane B2 levels, urinary protein excretion, and serum glucose in diabetic rats.
- Glomerular basement membrane thickness was significantly reduced in OKY-046 treated rats.
- Platelet aggregation was inhibited, while blood urea nitrogen remained unaffected.
Conclusions:
- Endogenous thromboxane A2 plays a significant role in the development and progression of diabetic nephropathy.
- Inhibiting thromboxane synthesis may be a therapeutic strategy for managing diabetic kidney disease.